The Food and Drug Administration said Friday it authorized a test developed by Adaptive Biotechnologies Corp. /zigman2/quotes/212846591/composite ADPT +3.15% that can detect the presence of a T-cell immune response, which can tell if someone has previously been infected with SARS-CoV-2. Adaptive's stock was up 11.0% in premarket trading on Monday. This type of test is different than antibody tests, which search for antibodies produced in response to a COVID-19 infection. The test, which has a sensitivity rate of 97.1%, was developed as part of a partnership with Microsoft Corp. /zigman2/quotes/207732364/composite MSFT +0.50% . "This is the first commercially available T-cell test that confirms recent or prior SARS-CoV-2 infections in people," Peter Lee, Microsoft's corporate VP of research and incubations, said in a news release. The test can be administered 15 days after someone experiences symptoms associated with infection. Adaptive's stock has gained 56.2% over the past 12 months, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.62% is up 27.0%.